Fair Value Calculator Fair Value Calculator
EN DE

2565 (2565) Fair Value & Analysis

Healthcare · Market cap HK$2.2B

2 2565 2565 · HK
PriceHK$5.69
Fair ValueHK$0.9900
Upside-82.6%
Quality35/100
Watch 2565 for free — get notified when fair value or trend changes. Watch for free
Evidence: Low Range HK$0.6500 – HK$1.24

Fair value as of: Jul 2, 2026

From 1 valuation models · updated today

Share price −29.9% over the past month.

Price vs Fair Value (12 months)

HK$74.65 HK$4.96 Fair Value HK$0.9900 Jun 2025 Jul 2026

12‑month range HK$4.96 – HK$74.65 · fair‑value band HK$0.6500 – HK$1.24 · the HK$5.69 price screens above the HK$0.9900 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

2565 (2565) currently trades at HK$5.69, while our model-based Fair Value estimate is HK$0.9900 — implying the stock looks roughly 82.6% overvalued today. We read business quality at 35/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

It earns a return on equity of -82.4%. Fundamentals as of Jul 2, 2026

Key figures & financial health

Return on equity -82.4%
Free cash flow −HK$156M FY2025
EPS (TTM) HK$-0.2500

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2022 – FY2025 · reported fiscal years

2565 reported revenue of HK$0 in FY2025 versus HK$0 in FY2022. Reported net income was −HK$208M in FY2025.

Revenue
FY22 HK$0
FY23 HK$0
FY24 HK$0
FY25 HK$0
Net income
FY22 −HK$306M
FY23 −HK$279M
FY24 −HK$283M
FY25 −HK$208M

Is 2565 fairly valued? → Check now

Similar stocks

6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX 7,746 MXN 5,617 MXN -27%
Regeneron Pharmaceuticals, Inc REGN $601.65 $577.20 -4%
UCB SA UCB €251.70 €180.06 -28%
argenx SE ARGNF $900.00 $390.80 -57%
Alnylam Pharmaceuticals, Inc ALNY $303.64 $110.31 -64%
Samsung Biologics Co 207940 1,000,000 KRW 724,332 KRW -28%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is 2565 (2565) undervalued?
As of Jul 2, 2026, our model estimates a fair value of HK$0.9900 versus a price of HK$5.69 — about −83% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 2565?
Our model-based fair value for 2565 is HK$0.9900 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$5.69.
What is the quality score of 2565?
2565 has a Quality Score of 35/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the net profit margin of 2565?
The net profit margin of 2565 is about 0.0%, meaning it keeps roughly 0.0% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.